Relatlimab: all 54 studies that test it

Page 1 of 1. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaNot yet recruitingNCT07459543Phase 4
• Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and RelatlimabRecruitingNCT06816927Phase 2
• Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesRecruitingNCT06712927Phase 2
• Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)RecruitingNCT06683755Phase 1/2
• Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell CarcinomaRecruitingNCT06624475Phase 2
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingNCT06561386Phase 3
• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaRecruitingNCT06295159Phase 2
• Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerRecruitingNCT06029270Phase 2
• Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyRecruitingNCT05987241Phase 2/3
• Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesRecruitingNCT05704647Phase 2
• Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AMLRecruitingNCT04913922Phase 2
• Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaRecruitingNCT04697576Phase 1
• Nivolumab for Treatment of Squamous Cell Carcinoma of the SkinRecruitingNCT04204837Phase 2
• Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
• Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaRecruitingNCT03521830Phase 2
• A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsActive, not recruitingNCT06101134Phase 2Results posted
• A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver CancerCompletedNCT05337137Phase 1/2Results posted
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaTerminatedNCT05255601Phase 1/2Results posted
• A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaTerminatedNCT05002569Phase 3Results posted
• A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)CompletedNCT04623775Phase 2Results posted
• A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase InhibitorsCompletedNCT04567615Phase 2Results posted
• Nivolumab Plus Relatlimab in Patients With Metastatic Uveal MelanomaCompletedNCT04552223Phase 2Results posted
• Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior ImmunotherapyCompletedNCT04326257Phase 2Results posted
• Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic SettingCompletedNCT03743766Phase 2Results posted
• Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II ExpressionTerminatedNCT03724968Phase 2Results posted
• Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal CancerCompletedNCT03642067Phase 2Results posted
• Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeCompletedNCT03493932Phase 1Results posted
• A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaActive, not recruitingNCT03470922Phase 2/3Results posted
• A Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaCompletedNCT02996110Phase 2Results posted
• A Study to Test Combination Treatments in Participants With Advanced Gastric CancerCompletedNCT02935634Phase 2Results posted
• An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT02750514Phase 2Results posted
• Neoadjuvant and Adjuvant Checkpoint BlockadeCompletedNCT02519322Phase 2Results posted
• An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsCompletedNCT01968109Phase 1/2Results posted
• Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.WithdrawnNCT07369791Phase 2
• Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)WithdrawnNCT06400264Phase 2
• Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaSuspendedNCT06325683Phase 2
• Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without RelatlimabActive, not recruitingNCT06237920Phase 2
• Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain MetastasesCompletedNCT05704933Early Phase 1
• Study of Relatlimab in Combination With Nivolumab in Chinese ParticipantsCompletedNCT05498480Phase 1
• A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous MelanomaActive, not recruitingNCT05418972Phase 2
• Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal MedullaActive, not recruitingNCT05347212Phase 2
• ARID1A and/or KDM6A Mutation and CXCL13 ExpressionActive, not recruitingNCT04953104Phase 2
• Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04658147Phase 1
• Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGITTerminatedNCT04150965Phase 1/2
• A Phase 1, Bioavailability Study of Relatlimab in Combination With NivolumabCompletedNCT04112498Phase 1
• Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck CancerActive, not recruitingNCT04080804Phase 2
• Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEGActive, not recruitingNCT04062656Phase 2
• A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) TreatmentTerminatedNCT03978611Phase 1
• An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaWithdrawnNCT03704077Phase 2
• Nivolumab and Relatlimab in Treating Participants With Advanced ChordomaCompletedNCT03623854Phase 2
• Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorActive, not recruitingNCT03607890Phase 2
• An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker AssessmentCompletedNCT03335540Phase 1
• Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal CancerActive, not recruitingNCT03044613Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2

← Relatlimab overview